MAFM
REGN icon

Mid Atlantic Financial Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mid Atlantic Financial Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-593
Closed -$243K – 770
2019
Q1 		$243K Sell
593
-41
-6% -$16.9K 0.03% 572
2018
Q4 		$237K Buy
+634
New +$232K 0.03% 536

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Mid Atlantic Financial Management's REGN Position: Q2 2019 in Review

Mid Atlantic Financial Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 593 shares — an estimated $243K sold.

Mid Atlantic Financial Management first reported a position in REGN in Q4 2018 and held it in 2 quarters. The position peaked at $243K in Q1 2019. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

  • Mid Atlantic Financial Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Mid Atlantic Financial Management sold 593 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $243K.
  • Mid Atlantic Financial Management first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Mid Atlantic Financial Management's Regeneron Pharmaceuticals position peaked at $243K in Q1 2019.
  • 658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Mid Atlantic Financial Management's 13F filing for Q2 2019, filed 6 Aug 2019.